Tyme Technologies Inc New (TYME) Quote

In the formal/ legal procedure of being merged with SYROS,it'll be simultaneous to aceptance of vote on Sept. 15th

At that MOMENT IN TIME, the current price of each pps will be factored into SYROS,
~ 73 million shares of TYME to derive the Reverse Split factor.

Note the use of APPROXIMATE
(~) in the 5th of July merger agreement
~~~~~~~~\\\\\\\\\\?~~~~~~~~~~
Per the terms, Syros (SYRS) will issue ~74.3M shares of its common stock to TYME investors, and TYME stockholders are entitled to nearly 0.4312 shares of Syros (SYRS) common stock for each TYME stock they hold.
~~~~~~~~~~~~~~~~~
At the posting TYME pps wa
-->0.3302.

That pps is devided into SYROS pps where apprx. 2.7 shares of TYME equalled 1 share of SYROS.

On the announcement, SYROS rose significantly from .87 to a buck. We stayed flat.

Pretty close

SEC filings released this morning Ocean. Just a month out till we're formally adopted:SEC FORM DEFM14A - 8/9/2022

SPECIAL MEETING NOTICE REGISTERED ON SEC's EDGAR Site

NOTICE IS HEREBY GIVEN that a virtual special meeting of stockholders, or the Syros special meeting, will be held on September 15, 2022, at 10:00 A.M. Eastern Time, unless postponed or adjourned to a later date. The Syros special meeting will be held entirely online. You will be able to attend and participate in the Syros special meeting online by visiting meetnow.global/MYRZKZT where you will be able to listen to the meeting live, submit questions and vote.

The Syros special meeting will be held for the following purposes:



1.
To approve, for purposes of Nasdaq Listing Rule 5635(a) and (d), the issuance of shares of common stock of Syros Pharmaceuticals, Inc., or Syros, to stockholders of Tyme Technologies, Inc., or Tyme, pursuant to the terms of the Agreement and Plan of Merger among Syros, Tyme and Tack Acquisition Corp., or Merger Sub, dated as of July 3, 2022, a copy of which is attached as Annex A to the accompanying joint proxy statement/prospectus, which is referred to in this Notice as the Merger Agreement, and to certain investors pursuant to the terms of the Securities Purchase Agreement, by and among Syros and the investors party thereto, dated as of July 3, 2022, a copy of which is attached as Annex F to the accompanying joint proxy statement/prospectus, which is referred to in this Notice as the Securities Purchase Agreement;


https://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=16001182-15542-28021&type=sect&TabIndex=2&companyid=873303&ppu=%252fdefault.aspx%253fsym%253dTYME

Consolidating nicely here until we revisit the .40's again next week

Another false alarm back to the .29 or so

Dont see any PRs ... is someone playing games? Or is something really going to be done for sure? Went up to .42 now fading.

Excellent

Just slapped .42

.38 AH's hmmmm

Think we'll see a move here soon in the next week to .40+

Good time to pick up TYME before the Syros merger. You'll wind up picking Syros at a good discount.

Annual shareholders' meeting and proxy vote ALWAYS IN August. Syros already had thei=s in June. About 1 .onth before the Merger announcement.

We ALL have to vote on it as a matter of course. The major holders already registered as being compliant with Boards of Directors.

From TYME Investor Relations today: "The meeting details will be disclosed within the next week or so."

After initial & minor PPS SURGE by SYRS on announcement, we've both stagnated.

My opinion? We'll have a joint meeting with merger consumated during it.

One big, happy family.

Musing. Expecting proxy ballots any day now for TYME & SYROS retail stockholders.

Also thinking the election to be simultaneous.

The pps for both have been pretty flat. Crappy Y-on-Y for all retailers. Beneficial holders have all signed off by SEC filings. One big family, waiting on consummation.

Thinking the timing on coming events have to be simultaneous to avoid wild PPS swings from day-traders which would skew the pre-agreed terms:

Excerpt ?July 5th Announcement (SYROS)
~~~~~~~~~~~~~~~~~
Upon the closing of the Merger, the Company expects to issue approximately 74.3 million shares of the Company’s common stock to Tyme stockholders,

Assuming that Tyme net cash as of the closing of the Merger is approximately $60 million and

Tyme stockholders are expected to receive approximately 0.4312 shares of the Company’s common stock for each share….
~~~~~~~~~~~~~~~~~
PPS of each July 5th ?17tt
—-------------------
Tyme .292 ?.296
Syrs .87?.93

Syros is set to pick up those cash reserves, which are expected to total $60 million after costs, by giving stock to Tyme shareholders. In conjunction with the merger, Syros has put together a private investment round. Syros’ founding investor Flagship Pioneering is participating in the $130 million financing with Avidity Partners, Deep Track Capital, Bain Capital Life Sciences, Invus and other backers.
Link:
https://www.fiercebiotech.com/biotech/buying-tyme-syros-inks-190m-merger-flagship-backed-financing-extend-cash-runway-2025

GLTUA

Quiet period should be over. Following is an RFI submitted to Investor Relations. This is as I understand the Merger.. ay be wrong. Hopefully, they'll straighten me outLisa, Jonathan,
May your weekend be as restful and joyous as you hope it will be.

Looking forward to our coming merger, and realizing the significant discounted price being given for Syros shares. Also appreciate the minimal reverse split required to somewhat balance the OS of the companies.

Still have concerns.
Syros is fast approaching a month-long PPS daily streak of <$1, and is approaching NASDAQ's low limit on keeping an exchage listing.
Syros is dominating the PRs, with acquisition of our cash at hand allows their expenses to be guaranteed covered through 2025. Nothing disclosed on TYME's operating costs?
->->->->->->->->
Will NASDAQ's non-compliance issue be addressed at our annual meeting?
We are waiting for the event schedule with ballot items detailed to be released.

What is the status of our clinical trials (HOPES and OASIS)?
May be expecting positive outcomes of each to bring our merged PPS over the low bar limit. That case equates to a desperate Hail Mary.

Hoping you can address these concerns.

VR

Yeah Ocean;
Our annual shareholder meeting is due up in August. We have to vote on rhis merger. From this excerpt::Upon the closing of the Merger, the Company expects to issue approximately 74.3 million shares of the Company’s common stock to Tyme stockholders, assuming that Tyme net cash as of the closing of the Merger is approximately $60 million and Tyme stockholders are expected to receive approximately 0.4312 shares of the Company’s common stock for each share ' a slight higher than a 2-to-1 Reverse Split. We wind up with a little less than half the shares we currently have.

Note, we're still less than a $buck with today,,'s pps. More deals coming.

MO.

So what do TYME shareholders get out of this? I hate these gobbledygook legal speak filings that just mention thing like unspecified share ratios. How about a PR with Plain English?

Concurrent with the merger, Syros announced an oversubscribed $130 million private investment in public equity (PIPE) financing at a price per unit of $0.94

I'm try to establish a session queue to view Hookipa's Annual Investor Meeting this morning.

Ahhhhhh. Not getting it.

Nuthing new on EDGAR for HOOK or TYME.
TYME's not holding our investor meeting till Augus

My Hookipa assumptions grew with the single page filing gaining the 6 month extension flimsy at best. SEC does allow proprietary/undisclosed filings. Like those filed controlling both founders' sell-downs.
Couple of other filings that I use to fantasize about how we're tied to HOOK.

March 25, 2022 ?TYME is pleased to announce that @@@@@ has been appointed to TYME’s Board of Directors.
Ms. @@@@@,,,,,,,currently the Chief Business Officer of Hookipa Pharma……

06/20/2022 HOOKIPA PHARMA ENTERED REGISTRATION RIGHTS AGREEMENT WITH GILEAD SCIENCES

Gilead Sciences, Inc. (GILD) - Hookipa Pharma Inc - on June 17, Entered Into a Registration Rights Agreement With Gilead Sciences, Inc.hookipa - Pursuant to Stock Purchase Agreement, Gilead is Required, at Company's Option, to Buy Up to $35 Million of Co's Common Stock.
÷÷÷÷÷÷÷÷÷÷÷÷÷÷=======
May not find out anything this morning. There would be news if plans are to merge with Hookipa???

Dunno. We'll see. Other than losses to date, still have hopes.

8K filing today. NASDAQ grants 6 month extension. No real action, other than notification of a REVERSE SPLIT if necessary.

This is the extent of the filing, other than all the entry field entries filled.
On June 21, 2022, the Company received notice from the Nasdaq Stock Market (“Nasdaq”) that it had granted the Company a 180-day extension to regain compliance with the Nasdaq continued listing standards. Nasdaq informed the Company that it granted the extension, in part, due to the Company’s intention to cure the deficiency during the extension period by effecting a reverse split, if necessary. The extension runs through December 19, 2022.

Interesting, ain't it Ocean:)?
This Seeking Alpha link will get you a month old article. Better than my BS. No insider buying to pump it up, but they've all been awarded plenty of options just above a $buck.

You're right, somebody does know. Acquisition would be great.
Thanks for dropping in, GLTUA. See what happens next Monday.

To get share price over $1.00 - either something like a 10 for 1 reverse split

or since they mentioned exploring strategic partnerships March 29th, sale of the company to a larger company. If price continues to rise - latter could be the case.
Someone seems to know something.

TYME ahhh Time's coming up,

7 Business Days till some kind of formal news will be released on our path forward. I sent this Investor request to IR relations and Jonathan Eckhard, Chief Business Officer[/quote]********************[/quote]
Retail Shareholders' Request -> End Period of Silence with Shareholder Teleconference r - June 20th

Good Day Lisa, Jonathan,
Requesting open discussion tele-con to held in conjunction with EDGAR filing detailing corporate path forward.

With only seven (7) business days, we have past any time limit imposed by NASDAQ to remain listed on a major exchange without any CLEAR PATH FORWARD detailed out formally.

From Corporate's 8-K registered 12/29/2021
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On December 22, 2021, the Company received notice from The Nasdaq Stock Market (“Nasdaq”) that the closing bid price for our common stock had
been below $1.00 per share for the previous 30 consecutive business days, and that we are therefore not in compliance with the minimum bid price
requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). Nasdaq’s notice has no
immediate effect on the listing or trading of our common stock on The Nasdaq Capital Market
.
The notice indicates that we will have 180 calendar days, until June 20, 2022, to regain compliance with this requirement. We can regain compliance
with the $1.00 minimum bid listing requirement if the closing bid price of our [url]common stock is at least $1.00 per share for a minimum of ten
(10) consecutive business days during the 180-day compliance period..
[/url][tag]insert-text-here[/tag]
Thank You in Advance for Consideration of this request.
Very Respectfully, [/quote]********************[/quote]

Disclosure statement from yesterdays's 10QOn December 22, 2021, the Company received notice from Nasdaq that the closing bid price for our common stock had been below $1.00 per share for the previous 30 consecutive business days, and that we are therefore not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). Nasdaq’s notice has no immediate effect on the listing or trading of our common stock on The Nasdaq Capital Market.
The notice indicates that we will have 180 calendar days, until June 20, 2022, to regain compliance with this requirement. We can regain compliance with the $1.00 minimum bid listing requirement if the closing bid price of our common stock is at least $1.00 per share for a minimum of ten (10) consecutive business days during the 180-day compliance period.
If the Company does not regain compliance during the initial compliance period, we may be eligible for an additional 180 day period to regain compliance. To qualify, we would be required to meet the continued listing requirement for market value of our publicly held shares and all other Nasdaq initial listing standards, with the exception of the minimum bid price requirement under Rule 5550(a)(2), and we would need to provide written notice to Nasdaq of our intention to cure the deficiency during the second compliance period. If it appears to Nasdaq that we will not be able to cure the deficiency, or if we are otherwise not eligible, we expect that Nasdaq will notify us that our common stock will be subject to delisting. We will have the right to appeal a determination to delist our common stock, and our common stock would remain listed on The Nasdaq Capital Market until the completion of the appeal process.
GLTUA

10K filed this morning. Link down at end. Here's a Seeking Alpha anaylist coverage piece (excerpt)
Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives
May 26, 2022 11:35 AM ETTyme Technologies, Inc. (TYME)
Summary
Tyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities.
After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives.
Board seems to be leaning towards a sale of the company.

https://seekingalpha.com/article/4514673-tyme-technologies-net-net-biopharma-exploring-strategic-alternatives?mailingid=27848581&messageid=2800&serial=27848581.369&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=27848581.369


https://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=15845110-950-563034&type=sect&TabIndex=2&companyid=873303&ppu=%252fdefault.aspx%253fsym%253dTYME

Dunno why the deeper turn down today. A little higher volume than normal. Short trades too.
¯\_(?)_/¯
Our founder sell downs going along as agreed by contracts. All public. What is newer, Dermegian voting shares will be following current board's recommendations. Share holder's meeting normally in August.
10Q for year end due in June. June 20th also end of our time for answering NASDAQ on plans to re-comply with OVER $1 PPS requirement.

Together, Durmegian and Hoffman, our founders who've been fired from operational roles are just a little shy of 40% of common stock. Data after last sale down below. If any interesting 8K is posted after hours, I'll post it here. Short registration recently lowered by ~34%. Shorts aren't moving us, may be holding us.

GLTUA, short data down below too.
Founder Name,,,,Date of Sale....Amount...Shares Still Held
Demurjian......05/17/2022......50000....23,408,846
Steve Hoffma....5/10/2022......78125....20,491,316

TYME
-0.02
Short Interest Ratio (Days To Cover) 2.2
Short Percent of Float1.18 %
Short % Increase / Decrease -34 %
Short Interest (Current Shares Short) 1,390,000
Short Interest (Prior Shares Short) 2,120,000
Shares Float 117,480,000

GLTUA

Nuts. RFI sent to Investor Relations. Last Friday after close, the files for our ongoing Ewings Sarcoma were updated. Single entry moving out preliminary study to October 2022. It was already overdue.

Here's what I asked:

Thank You ### for call last week. Much appreciated. I realize we're in a quiet period, however, current share price dive should be acknowledged somehow. Just laying out some concerns here.

Files attached for reference only, pretty sure you both know all about them.
History of Changes for Study....generated at Clinical Trials.gov site. This version posted last Friday, on our Sarcoma study with Joseph Ahmed Fund. Only change was the extending the already overdue trial study by a year. To October, 22.

#######, on previous discussions, you did address my note on this to be completed the 2nd half of FY 22. This posting seems to be the only reason for our crash.

Pre 14A is HookIPA's public notice of Share Holders' Meeting at the end of June, and the proxy measures to be on the ballot.
This is just an association I've formed with their CEO put on our board as a non-executive Director. One of my points on this transmittal being IF we're waiting on HOOK, it's too late for many of us.
Our annual earnings have been early June recently, This year, our NASDAQ action plan is also due during June.
Shareholders in August,
Reverse split (as pme of HookIPA's ballot measures) with our PPS diving is passed unacceptable if released on a Form 14 or amended version.

That's about it. Asking for some method of Public Announcements be made ASAP to assure or at least acknowledge the real concerns of retail holders.

Very Respectfully,
************************************
Only public record I can find that may be related to our dive is the Clinical Trial history record for NCT03778996 . A couple of date changes. Current filing obviously and then moving out the actual PRELIMINARY reporting date to this October.


The HOOKIPA 14A is available on EDGAR. Has their proxy vote items on it. Just for &&& and Grins. Hannah told us about it.
GLTA

Well Bagel, since you got me started. TYME Earnings Date
Well DAMN. Just been told by Investor Relations that we're in A QUIET PERIOD, so they can't answer any of my questions.

Last year ANNUAL EARNINGS report was early June. Talking heads are estimating June 9th. So it goes. I've asked for several items I ain't getting:

(1)Request for abstract and chart we presente at American Association for Cancer Research (AACR)2022, Abstract 4122,SM-88.

(2) Insight on last week's weird option awards (low strike price, long term).

And this last one we got from a poster #AnnaH over on our sister site hosted by Yahoo Finance about two days ago:

(3)HOOKIPA promotes Christine D. Baker to Chief Operating Officer
MAY 2, 2022……..She currently serves as a non-executive Director of the Board of Tyme Technologies.

INTERESTING at least to me. With earnings coming, perfect time to announce a merger?:). Cause we have to vote on that and Shareholders meetings with ballot measures be held in August.

Here's some links to Hookipa's latest SEC filings. Including some key points held on their presentation:

HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook March 24, 2022
https://ir.hookipapharma.com/node/8126/pdf

(1)Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patients

(2)HOOKIPA received FDA Fast Track designation and advanced HB-200 to Phase 2 trial in combination with pembrolizumab, with data anticipated in H2 2022

(3)HOOKIPA and Gilead agreed to advance partnered HIV program, triggering $54 million commitment from Gilead

(4)Strong 2021 year-end pro forma cash position of $156.9 million when giving effect to payments received in Q1 2022 from Gilead transaction and proceeds of $75 million public follow-on offering

New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens April 13, 2022
https://ir.hookipapharma.com/node/8181/pdf

¯\_(?)_/¯

Sorry about the late reply Bagel. Been a bit since on this site. Didn't have any info, AND, licking my wounds:). A Yahoo poster found this, andddddd, MAYBE a possible merger on the table????[quoteHOOKIPA promotes Christine D. Baker to Chief Operating Officer
MAY 2, 2022……..She currently serves as a non-executive Director of the Board of Tyme Technologies.
About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize……https://www.citybiz.co/article/255215/hookipa-promotes-christine-d-baker-to-chief-operating-officer/[/quote]¯\_(?)_/¯.
Investor Relations incommunicado about any topics submitted on RFIs. Nuthin on the HOPES Sarcoma trial. Small, real small clinic running that. Can't find much on it. On OASIS, been running long enough for some trial data to be available.

Disappointed. The merger???? I just don't know. Not looking at loading up. Did that a couple of months ago. More now accumulated then a pig can $#!*< sorry> Something I can only hope to see.
GLTUA

Is there ANY way this thing turns back to $2.+ ???

8K filed on Monday. Just a share-selling agreement with Red Bank Mike Dumerjian (one of our founders) and TYME. Red Bank** Mike selling off for lunch money. Red Bank, New Jersey is his incorporated Home of Record)
¯\_(?)_/¯
Ahhh. Mike is currently holding 23,688,846 after last sale, as reported on his last Form 4.
Here's the meat:

Item 1.01.
Entry into a Material Definitive Agreement.

Voting Agreement and Release Agreement Amendment

The Company and Michael Demurjian entered into a Voting Agreement, dated April 18, 2022 (the “Voting Agreement”), pursuant to which Mr. Demurjian agreed to vote all shares of TYME common stock beneficially owned by him in accordance with the board of directors of the Company’s recommendation with respect to any matter presented to the Company’s stockholders for a period of two years from the date of the Voting Agreement.

In connection with entering into the Voting Agreement, the Company and Mr. Demurjian also entered into an amendment to the Release Agreement that the Company previously entered into with Mr. Demurjian on March 15, 2019 (the “Release Agreement” and the amendment thereto, the “Release Agreement Amendment”). Under the Release Agreement, Mr. Demurjian is subject to certain sale limitations imposed through March 5, 2024 (the Fall-Away Date”). As part of the Release Agreement Amendment, Mr. Demurjian’s sale limitations will remain in place through Fall-Away Date, however, he is now able to sell more Company shares on a bi-weekly basis, which number of shares per period will increase over time (such periods being the weekly trading days on which The Nasdaq Stock Market is open during an individual week, with such periods occurring every other week). Beginning the week of April 18, 2022, Mr. Demurjian will be able to sell up to 40,000 shares a day on two consecutive days for a total of up to 80,000 shares per period, increasing up to 80,000 shares a day on two consecutive days for up to 160,000 shares per period.

Just in case you haven't realized: Today is the last day of FY 2022.

And this notification registered on an 8k on Tuesday
¯\_(?)_/¯
TYME Technologies, Inc. Announces Exploration of Strategic Options ?March 29 2022 - 06:50AM

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value. The Company has engaged Moelis & Company LLC as its financial advisor and Faegre Drinker Biddle & Reath LLP as its legal advisor.

On January 26, 2022, TYME announced the discontinuation of a randomized Phase II/III trial of SM-88 in combination with methoxsalen, phenytoin, and sirolimus (MPS) for patients with metastatic pancreatic cancer upon learning that the trial sponsor terminated the study arm due to futility. Notwithstanding the discontinuation of its most advanced clinical trial, the Company believes there are additional opportunities that could enhance value for TYME stockholders. TYME believes that being well-capitalized affords it the ability to consider a wide range of strategic options and therefore has commenced a formal process with Moelis & Company LLC.

The Strategic Planning Committee of the Board will act as a Transaction Committee and will be led by TYME Board Member Timothy C. Tyson, who possesses over 35 years of biotechnology and pharmaceutical industry experience, including multiple M&A transactions. There can be no assurance that this process will result in any such transaction, and the Company does not intend to disclose additional details unless and until it has entered into a specific transaction.

“The goal of the strategic evaluation process is to ensure that we are exploring a range of possible options to maximize value for our stockholders. With $92 million in cash and marketable securities as of December 31, 2021, we believe that TYME is in a strong position to find an advantageous transaction,” stated Richie Cunningham, Chief Executive Officer of TYME.

TYME continues to evaluate SM-88 in two separate Phase II investigator-sponsored studies in HR+/HER2- breast cancer and sarcoma. A poster presentation from the Phase II OASIS study of SM-88 in patients with HR+/HER2- breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 11, 2022. The Company is also conducting a comprehensive translational preclinical program focused on SM-88 MOA and Biomarker Identification/Validation and has engaged Evotec, a leading global research and development company, to aid in the execution of these activities

Tyme to sell.

After Hours 8-K released on EDGAR. Provides a brief about our ASCO show and the link to our POSTER.

HUGE file size byte wise and physically Makes it a little tough, AND, can't eat this elephant all at once.

https://tymeinc.com/data-publications/scientific-presentations/default.aspx?_ga=2.14989942.1910725466.1642085084-49066985.1641324922

Jan 20-22, 2022 Moscone West • San Francisco, CA & Online #GI22
Abstracts and Posters for the 2022 Gastrointestinal Cancers Symposium are available for searching. Posters will be released at 8 AM ET on the first day of the symposium. Online posters are available for download on the ASCO Meeting Library beginning the same day, but the specific timing depends on uploading by individual presenters.


Little teaser available in a couple of AGENDA files

This excerpt found in the test handout accompanying the POSTER that's not available.

Conclusions:
This final analysis confirmed that SM-88 Regimen was well tolerated, with patients attaining an overall Disease Control Rate (DCR) of 27%.

Of note, for the small subset of patients treated in the second line, the mOS and mPFS were on par
with results achieved in other published randomized PhIII second-line trials for mPDAC.


Moreover, SM-88 Regimen exhibited far fewer Grade 3 and 4 AEs than other commonly used cytotoxic regimens in the second line. The 27% DCR, 8.1 mo mOS, and 3.8 mo mPFS in the second line, with minimal toxicity and preserved QOL, resulted in the active investigation of SM-88 Regimen in a large, ongoing second-line trial in mPDAC (NCT04229004).

Clinical trial information: NCT03512756. Research
Sponsor: TYME Inc.

Oral SM-88 plus MPS, an effective yet less toxic treatment option in second-line
advanced pancreatic cancer? Final phase II/III study results.

This link will get you a detailed file of all the projects being presented. Ours is on the 67th pdf page

..........................
Disease Control Rate (DCR) and Clinical Benefit Rate (CBR) are defined as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents

mOS. Median OS. Medical ; 1. MOS. Median Overall Survival ·

I'm encouraged to believe our presentations at ASCO's fast approaching symposium will certainly bring us, and keep us well over a $buck.

American Society of Cancet Oncologists' (ASCO's) symposiums introduce and update therapeutic developments.

We've been introduced and progress noted in admittedly small clinical trials..Trial data for both our Sarcoma and Pancreatic are due.
______________________
Here's the MPS drug regimine concurrent with SM-88


trial(s) ,,,, designed to evaluate the safety and efficacy of SM-88 used with MPS (methoxsalen (1), phenytoin(2) and sirolimus) in pancreatic cancer and will measure multiple endpoints, including overall survival, progression free survival, relevant biomarkers, quality of life, safety, and overall response rate.

…..(1) Methoxsalen - used with UV light on skin to prevent severe psoriasis
…..(2) Phenytoin - Anti-seizure and –convulsant used to control certain type of seizures, and to treat and prevent seizures that may begin during or after surgery to the brain or nervous system. Phenytoin is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain
….(3) Sirolimus - immuno suppressants
O______________________
This year's ASCO shindig Annie excerpt

TYME Technologies, Inc. (Nasdaq: …... Oral SM-88 plus MPS, an effective yet less toxic treatment option in second-line advanced pancreatic cancer.
Final phase II/III study results, has been accepted for poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 20 – 22, 2022, in San Francisco, CA.
________________________Excerpts from Last Year's cocktail party :)

Journal of Clinical Oncology - published online before print January 22, 2021

Phase II/III Study of SM-88 in Patients with Metastatic Pancreatic Cancer.

Randomized and evaluable subjects (n=38) included mean age 65y (45-86);
BMI 24.6 (18.8-38.7); female 39.5%; White 76.3%. Of treated subjects 65.8% (25/38) had 166 AEs, with 25.7% (26/101) being at least possibly SM-88-related
______________<_________

Well, Richie Cunningham was enthusiastic. Keeping with the same development schedule using calander year in half-year increments. So in this half, Sarcoma is on the dock.

He was real upbeat. Slide show supposed to be released. I'm sure it is.

Well, Richie Cunningham was enthusiastic. Keeping with the same development schedule using calander year in half-year increments. So in this half, Sarcoma is on the dock.

He was real upbeat. Slide show supposed to be released. I'm sure it is.

Screwed up yesterday's postings. Tripled the first. Ahhhhh.

Good Morning. Thanks Bagel for the HC Wainwright showing coming up.
Executive Officer, and Jonathan Eckard, Chief Business Officer, will present at the H.C. Wainwright Bioconnect Virtual Conference as follows:
Monday, January 10, 2022

https://journey.ct.events/view/8689e139-56fc-489f-a7ff-f600798ac5b3

The presentation will be available on demand beginning on January 10, 2022, at 7:00 a.m. ET and will be accessible on the Events & PresentationsGuessing there won't be any news till then.
GLTUA

Cool! At 100k now myself Bagel!

I think we are in great shape. The founders sell downs are really understandable. They both LOST a hellua lot to date and only paring down their SUPER SIZED holding.

Here's a PANCAN Site link
[url]Two Pancreatic Cancer Clinical Trials Fail to Improve Overall Survival - Pancreatic Cancer Action Network

https://www.pancan.org/news/two-pancreatic-cancer-clinical-trials-fail-to-improve-overall-survival/

So RAFL fell 75% but they were at $35. Gotta go. Boss is calling

Hey Mike, Been in TYME for a long time as well. Can't imagine that they are going to present at HC Wain and not have some kind of good news. HC is the only one that covers them with a buy rating. Not concerned with the selling as Hoff has about 25,000,000 shares, at this point i think at 20k is not much.
Holding strong as i added more today...100k+ shares as of now. they have plenty of $$$ and a few big guys in at $2 or more. 2022 should be good. I will trim some at 7 and then on the way up. I believe this stock can be well above 30 not too long from now

Poking around about last month's 8k listing a press-release on the status of TYME's COVID-19 sidebar project

TYME-19 (COVID project) was first announced in August 2020. Under the old Board of Directors, all swept OUT of offices held when we got $100 million Institutional buy in.

New CEO, Richie Cunningham, had one mention of TYME-19 in passing. All focus moving our R&D assets to:
....(1) Jump-start our dormant Breast Cancer Therapy
Trial .
....(2) Continue our collaborative trials in pancreatic and sarcoma cancers.

Cunningham has indicated he wasn't into Press Releases once underway. 8k registrations ln project developments would be where our progress is listed.

Most missed the close timing between the 8k/PR and Army's own COVID announcement. Couple of returns on same search on web follow.

Series of preclinical studies supports the Army's pan-coronavirus vaccine Dec 16, 2021 — – A series of recently published preclinical study results show that the Spike Ferritin Nanoparticle (SpFN) COVID-19 vaccine developed by ...

TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data ...
Dec 14, 2021 — The Company believes that TYME-19, a synthetic bile acid, may have differentiated mechanisms that could offer alternatives for COVID-19 ...

Just intesting fo me. Army and TYME both finding success in micro-biological processes that have similar molecular proteins and acids. Then it gets complicated.

Nuther note. The bi-weekjy sell-downs by our founder who together still hold 45 million shares around 1/3d of whole OS.

They are sideliners more than insiders. Demurjian kicked out after a n error in judgement in 2019 on a small breast cancer trial.

Hoffman pushed out in 2020 with the $100 mill buy in and arrival kf Richie Cunningham. By the registrations with SEC, each sell down is controlled as incremental. Only 4-to-8% of each foundeing-sidelinerd' holdings are registered.

First half of calendar year 2022 is supposed to hold great news on sarcoma. Maybe COVID as well.

Staying long. We have a whole new Board of Directors since the $100 mill.

Things are moving.
Good Luck to us all

After Hour 8k filed on EDGAR, acknowledging non-Compliance notification received from NASDAQ
Introductory Comment – Use of Terminology

Throughout this Current Report on Form 8-K, the terms “the Company,” “we” and “our” refer to Tyme Technologies, Inc., a Delaware corporation, together with its subsidiaries (“TYME”).



Item 3.01.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On December 22, 2021, the Company received notice from The Nasdaq Stock Market (“Nasdaq”) that the closing bid price for our common stock had been below $1.00 per share for the previous 30 consecutive business days, and that we are therefore not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). Nasdaq’s notice has no immediate effect on the listing or trading of our common stock on The Nasdaq Capital Market.

The notice indicates that we will have 180 calendar days, until June 20, 2022, to regain compliance with this requirement. We can regain compliance with the $1.00 minimum bid listing requirement if the closing bid price of our common stock is at least $1.00 per share for a minimum of ten (10) consecutive business days during the 180-day compliance period.

If the Company does not regain compliance during the initial compliance period, we may be eligible for an additional 180 day period to regain compliance. To qualify, we would be required to meet the continued listing requirement for market value of our publicly held shares and all other Nasdaq initial listing standards, with the exception of the minimum bid price requirement under Rule 5550(a)(2), and we would need to provide written notice to Nasdaq of our intention to cure the deficiency during the second compliance period. If it appears to Nasdaq that we will not be able to cure the deficiency, or if we are otherwise not eligible, we expect that Nasdaq will notify us that our common stock will be subject to delisting. We will have the right to appeal a determination to delist our common stock, and our common stock would remain listed on The Nasdaq Capital Market until the completion of the appeal process.

We intend to actively monitor the minimum bid price of our common stock and may, as appropriate, consider available options to regain compliance with Rule 5550(a)(2). However, there can be no assurance that the Company will be able to regain compliance with Rule 5550(a)(2).
GLTUA

Peace, Health, Happines, Love be Yours now and forever
Prosperity for the New Year WILL be nice.
Blessings to Yours

Sorry for the long delay Chillin', had to put down my watch on this, been waiting for our IR rep response to my same question. Nuthin yet.

Negative thoughts being this just a pump to stabilize then jump over a buck for a day or two to stave off NASDAQ notice of concern.

Still maybe that. Cunningham,z been lukewarm on TyME19. Here's the August 2020 storybook startTYME’s Oncology Research Reveals Potential New Oral Therapy TYME-19 in the Fight Against COVID-19 - Bloomberg

https://www.bloomberg.com/press-releases/2020-08-26/tyme-s-oncology-research-reveals-potential-new-oral-therapy-tyme-19-in-the-fight-against-covid-19 Tuesday's news kind of a cut and paste.
.So WTF? I'LL Bug IR again. Dunno

BEDMINSTER, N.J.--(BUSINESS WIRE)--Dec 14, 2021--

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced encouraging preclinical data on the effect of TYME-19 in SARS CoV-2 infections.

Agreed.

Interesting podcast that highlights the Warburg effect and role in cancer.

https://peterattiamd.com/samapple/

Any insight on the pr from today? Seems like 2022 may finally be our year

Insider support set at 95¢ pps by 3.ALMOST identical after-hours SEC filings with Form 4s

Barb.Galaini....10,000.....A... $0.95
James Biehl…..….10,000 ….A... $0.95
Frank Porfido…...10,000.....A ... $0.93

Start of additional insider trades incrementally pushing and holding above a $buck¯\_(?)_/.

Feeling like we're getting shored up vs. blasting off. Not thrilled but I'll take it.

Dam, Dam, double dam
After hours S-8 filed after hours. 3 million new shares registered for insider fire sale.
$1.01 strike price.
+++++++++++++++++++
This Registration Statement (this “Registration Statement”) is filed pursuant to General Instruction E to Form S-8 and consists of only those items required by General Instruction E. This Registration Statement is being filed by the Registrant to register the issuance of an additional 3,000,000 shares of Common Stock of the Registrant, that may be awarded under the 2016 Plan. The contents of the Registrant’s previous Registration Statements on Form S-8 filed on August 10, 2017 (File No. 333-219856) and August 28, 2018 (File No. 333-227077) relating to the 2016 Plan are incorporated herein by reference and made a part hereof.

Good point Muroc! And that's the only news I can stretch into happening:). Got an RFI in to the clinic's point-of-contact for personal therapy:)

Don’t think there will be any data until sometime after enrollment is complete.

Murocman

From yesterday's 10Q. Description of the trial that seems to have some data released SOON. Corporate coverage. The 10Q has a glossary for the terms entered here:[/quote]HoPES Phase II Trial in Sarcoma
In early 2020, the open-label Phase 2 investigator sponsored trial of SM-88 therapy in sarcoma, ….
(1) The first is SM-88 with Methoxsalen*, Phenytoin**, and Sirolimus*** (MPS) as salvage treatment in patients with mixed rare sarcoma.
(2) The other is SM-88 with MPS as maintenance treatment for patients with metastatic Ewing’s sarcoma that had not progressed on prior therapy.[/quote]
The primary objectives are to measure:
………Objective Response Rate (ORR) and
……….Progression Free Survival (PFS).
Secondary objectives include:
……..Duration Of Response (DOR)
……..Overall Survival (OS)
……..Clinical Benefit Rate (CBR) using RECIST (Response Evaluation Criteria In Solid Tumors)[/quote]
Plus incidence of treatment-emergent Adverse Events (AEs).
The Joseph Ahmed Foundation is sponsoring this trial and the trial is being conducted by PI Dr.Chawla at the Sarcoma Oncology Center in Santa Monica, CA.

We anticipate that the trial will complete enrollment by the end of the first half of calendar year 2022.